The Food and Drug Administration Monday approved the first drug to treat Duchenne muscular dystrophy, a rare and lethal muscle weakening disorder that affects about 15,000 Americans.
The FDA鈥檚 of the drug, Exondys 51, also known generically as eteplirsen, came over the objections of its own advisory committee, which voted not to approve the medication earlier this year. Patients and their families had lobbied hard for the drug, made by Sarepta Therapeutics of Cambridge, Massachusetts, noting that people with the disease have few treatment options.
A Sarepta spokesman said the company plans to announce the price of the drug during a 4 p.m. conference call today.聽Exondys 51 could sell for $350,000 a year, according to Michelle Gilson, an analyst for Oppenheimer & Co., an investment bank.
Exondys 51 doesn鈥檛 cure Duchenne muscular dystrophy and will only help a minority of patients. It is designed for the 13 percent of patients with a particular genetic mutation that prevents them from making dystrophin, a key protein that keeps muscles intact. Without that protein, muscles weaken so that children are unable to walk and must use wheelchairs by the time they鈥檙e teens. Eventually, the disease can fatally weaken the heart and muscles needed to breathe. Patients often die in their 20s or 30s.
The FDA鈥檚 decision speeds up the approval process for Exondys 51, allowing it onto the market based on preliminary data that suggests the drug will strengthen children鈥檚 muscles, even though the company has not yet produced clear proof that the medication will delay paralysis or improve symptoms.
In clinical trials, some patients treated with Exondys 51 had more dystrophin in their skeletal muscles, which people use to move their arms and legs. The FDA will require Sarepta to launch another clinical trial to show whether it actually improves patients鈥� symptoms. If the drug doesn鈥檛 help, the FDA could withdraw approval.
Sarepta鈥檚 stock price jumped 90 percent Monday after the approval was announced. The company鈥檚 stock also got a bounce last week after the FDA confirmed a staff member who had been critical of the drug, Dr. Ronald Farkas, had for another job.
Farkas had expressed doubts about the drug鈥檚 effectiveness during a review of Exondys 51 earlier this year.
Duchenne muscular dystrophy occurs in about one out of every 3,600 baby boys worldwide, according to the FDA.
The disease is so rare that the FDA considers it an 鈥渙rphan disease,鈥� or one that isn鈥檛 common enough to attract many drug developers. The FDA encourages companies to develop drugs for orphan diseases by giving them special tax credits and extending the amount of time that companies are able to sell them exclusively, without generic competition.
Pat Furlong, president and CEO of the advocacy group Parent Project Muscular Dystrophy, said the FDA made the right call in approving the drug. 鈥淭his acknowledges that the patient voice is important,鈥� Furlong said.
Advocates say they hope the approval will be the first of many.
鈥淚t鈥檚 a huge step forward,鈥� said Dr. Valerie Cwik, executive vice president and chief medical and scientific officer at the Muscular Dystrophy Association, which advocates on behalf of patients and their families. 鈥淚t鈥檚 a really, really big day for the Duchenne community.鈥�
Developing a drug for rare diseases like this is complicated by the 鈥渟mall numbers of people affected by each disease and the lack of medical understanding of many disorders,鈥� said Janet Woodcock, director of the FDA鈥檚 Center for Drug Evaluation and Research. 鈥淎ccelerated approval makes this drug available to patients based on initial data, but we eagerly await learning more about the efficacy of this drug through a confirmatory clinical trial that the company must conduct after approval.鈥�
The most common side effects from Exondys 51 include vomiting and problems with balance.
Some health advocates criticized the FDA鈥檚 decision.
Overruling the advisory committee shows 鈥渁 disturbing disregard for the agency鈥檚 聽legal standards for approving new drugs,鈥� said Michael Carome, director of Public Citizen鈥檚 Health Research Group, a nonprofit that studies drug safety. 鈥淚n particular, such action eviscerates the agency鈥檚 long-standing requirement that there be substantial evidence of effectiveness for new drugs 鈥� even drugs for serious rare diseases 鈥� before they are marketed.鈥�
Diana Zuckerman, president of the National Center for Health Research, a nonprofit research group, noted that the Exondys 51 clinical trial was poorly done. Doctors leading the trial didn鈥檛 compare patients who received the drug with a 鈥渃ontrol group鈥� of untreated patients.
鈥淚t sets a dangerous precedent if the FDA is going to start approving drugs that aren鈥檛 compared to anything,鈥� Zuckerman said. 鈥淲hy would a company choose to do a careful, well-designed study that might show that its product isn鈥檛 particularly safe or effective if it can get away with doing a tiny, poorly designed study with ambiguous results?鈥�
Laura McLinn, an Indiana mother whose 7-year-old son has Duchenne muscular dystrophy, was in tears Monday when she heard the news of the drug鈥檚 approval. Although her son isn鈥檛 eligible to take Exondys 51, because his disease is caused by a different mutation, McLinn said she hopes the approval will speed the development of another drug in Sarepta鈥檚 pipeline, which could help her son. She hopes he could enter a clinical trial by the end of the year.
鈥淚鈥檓 really overwhelmed,鈥� McLinn said. 鈥淲e鈥檝e been waiting a long time to hear this.鈥�
The news of FDA approval for Sarepta鈥檚 drug follows the agency鈥檚 rejection of another highly touted treatment for Duchenne. In January, the agency ended months of uncertainty about the drug Kyndrisa after a panel of advisers found that the drug鈥檚 effectiveness in trials did not conclusively show improved walking ability in patients. BioMarin Pharmaceuticals has since announced it was abandoning development of Kyndrisa.
Sarah Jane Tribble contributed to this report.
KHN鈥檚 coverage of prescription drug development, costs and pricing is supported in part by the .